Paris-Saclay University, Paris-South University, UVSQ, Center for Research in Epidemiology and Population Health, INSERM, 16 Avenue Paul Vaillant Couturier, 94807, Villejuif Cedex, France.
Santé publique France, French Public Health Agency, Direction Santé Environnement Travail, Saint-Maurice, France.
Eur J Epidemiol. 2022 May;37(5):513-523. doi: 10.1007/s10654-022-00851-y. Epub 2022 Mar 14.
Parkinson's disease (PD) is an uncommon disease with a long prodromal period and higher incidence in men than women. Large cohort studies of women with a long follow-up are needed. Within the E3N French cohort study (98,995 women, 40-65 years at baseline), we identified 3,584 participants who self-reported PD or used anti-parkinsonian drugs over 27 years (1992-2018). We obtained medical records to validate PD diagnosis (definite, probable, possible, no). When medical records were not available, we used a validated algorithm based on drug claims to predict PD status. We retained a PD diagnosis for 1,294 women (medical records, 62%; algorithm, 38%). After exclusion of prevalent/possible cases, cases without age at diagnosis, and women lost to follow-up, our analyses included 98,069 women, of whom 1,200 had incident PD (mean age at diagnosis = 71.8 years; incidence rate = 0.494/1,000 person-years). Age-adjusted incidence rates increased over the six first years of follow-up, possibly due to healthy volunteer bias, and remained stable thereafter, similar to incidence rates in women from Western Europe. Forty three percent of PD cases occurred after 20 years of follow-up (2012-2018). The cumulative incidence of PD from 50 to 90 years was 2.41% (95% confidence interval [CI] = 2.27-2.65). PD incidence was lower in ever than never smokers (hazard ratio = 0.86, 95% CI = 0.76-0.96). In conclusion, we estimated PD incidence rates in French women over a 27-year follow-up, and showed stable incidence between 2002 and 2018. The long follow-up and large sample size make this study a valuable resource to improve our knowledge on PD etiology in women.
帕金森病(PD)是一种罕见疾病,具有较长的前驱期,且男性发病率高于女性。需要对有长期随访的女性进行大型队列研究。在 E3N 法国队列研究(98995 名女性,基线时年龄为 40-65 岁)中,我们确定了 3584 名在 27 年内(1992-2018 年)自我报告患有 PD 或使用抗帕金森病药物的参与者。我们获得了医疗记录以验证 PD 诊断(明确、可能、可能、无)。当无法获得医疗记录时,我们使用基于药物索赔的经过验证的算法来预测 PD 状态。我们保留了 1294 名女性(医疗记录,62%;算法,38%)的 PD 诊断。排除现患/可能病例、无诊断年龄的病例和随访丢失的女性后,我们的分析纳入了 98069 名女性,其中 1200 名患有新发 PD(诊断时的平均年龄为 71.8 岁;发病率为 0.494/1000 人年)。调整年龄后的发病率在随访的前六年中增加,可能是由于健康志愿者的偏倚,此后保持稳定,与来自西欧的女性的发病率相似。43%的 PD 病例发生在随访 20 年后(2012-2018 年)。50 岁至 90 岁的 PD 累积发病率为 2.41%(95%置信区间 [CI] = 2.27-2.65)。曾经吸烟者的 PD 发病率低于从不吸烟者(风险比 = 0.86,95% CI = 0.76-0.96)。总之,我们估计了法国女性在 27 年随访期间的 PD 发病率,并显示 2002 年至 2018 年之间的发病率稳定。长期随访和大样本量使这项研究成为一个宝贵的资源,可以提高我们对女性 PD 病因的认识。